Showing results (1-10 of 1,154) with videos related to
Sort By:
Pageof 116
Leukemia & Lymphoma|October 3, 2018
Characterizing the kinetics of lymphocytosis in patients with chronic lymphocytic leukemia treated with single-agent ibrutinibJacqueline C Barrientos, Jan A Burger, John C Byrd, et al.Blood|February 14, 2018
Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experienceSusan O'Brien, Richard R Furman, Steven Coutre, et al.Future Oncology (London, England)|February 7, 2007
Alemtuzumab in chronic lymphocytic leukemiaDanelle F James, Thomas J KippsAdvances in Therapy|July 5, 2011
Rituximab in chronic lymphocytic leukemiaDanelle F James, Thomas J KippsBlood|February 21, 2015
Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinibJohn C Byrd, Richard R Furman, Steven E Coutre, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 12, 2017
Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaSteven E Coutré, Richard R Furman, Ian W Flinn, et al.Journal of the National Comprehensive Cancer Network : JNCCN|May 24, 2014
Chronic lymphocytic leukemia: state of the art and beyondJohn C ByrdCancer|July 13, 2006
Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemiaStefan Faderl, Kanti Rai, John Gribben, et al.Cancer Discovery|September 3, 2017
Spotlight on Ibrutinib in PCNSL: Adding Another Feather to Its CapAparna Lakshmanan, John C ByrdCancer Discovery|July 31, 2015
Mass Cytometry: A High-Throughput Platform to Visualize the Heterogeneity of Acute Myeloid LeukemiaPriscilla Do, John C ByrdPageof 116